References:
1. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biology of Blood and Marrow Transplantation. 2008;14(6):641-50.
2. Al Malki MM, Yang D, Labopin M, Afanasyev B, Angelucci E, Bashey A, et al. Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. Blood advances. 2020;4(9):2073-83.
3. Law AD, Salas MQ, Lam W, Michelis FV, Thyagu S, Lipton JH, et al. Reduced-intensity conditioning and dual T lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplants for hematological malignancies. Biology of Blood and Marrow Transplantation. 2018;24(11):2259-64.
4. Wang Y, Wu D-P, Liu Q-F, Xu L-P, Liu K-Y, Zhang X-H, et al. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. Journal of hematology & oncology. 2019;12(1):1-9.
5. Xu X, Yang J, Cai Y, Li S, Niu J, Zhou K, et al. Low dose anti-thymocyte globulin with low dose posttransplant cyclophosphamide (low dose ATG/PTCy) can reduce the risk of graft-versus-host disease as compared with standard-dose anti-thymocyte globulin in haploidentical peripheral hematopoietic stem cell transplantation combined with unrelated cord blood. Bone marrow transplantation. 2021;56(3):705-8.
6. Makanga DR, Guillaume T, Willem C, Legrand N, Gagne K, Cesbron A, et al. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution. The Journal of Immunology. 2020;205(5):1441-8.
7. Passweg J, Baldomero H, Bader P, Bonini C, Duarte R, Dufour C, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone marrow transplantation. 2017;52(6):811-7.
8. Phelan R, Arora, M., Chen, M. . Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides. 2020.
9. Bhushan V, Mathews J, Vance E, Escobar C, Kurre J, Potter J, et al. Salvage Therapy for Graft Rejection with Second Haploidentical Allogeneic Stem Cell Transplantation (Haplo-HCT) from a Second Related Donor. Biology of Blood and Marrow Transplantation. 2015;21(2):S297.
10. Prata PH, Resche-Rigon M, Blaise D, Socié G, Rohrlich P-S, Milpied N, et al. Outcomes of salvage haploidentical transplant with post-transplant cyclophosphamide for rescuing graft failure patients: a report on behalf of the francophone society of bone marrow transplantation and cellular therapy. Biology of Blood and Marrow Transplantation. 2019;25(9):1798-802.
11. Yoshihara S, Ikegame K, Taniguchi K, Kaida K, Kim E, Nakata J, et al. Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning. Bone marrow transplantation. 2012;47(3):369-73.
12. Epperla N, Pasquini M, Pierce K, Drobyski W, Rizzo J, Horowitz M, et al. Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. Bone marrow transplantation. 2017;52(1):147-50.
13. Giammarco S, Raiola AM, Di Grazia C, Bregante S, Gualandi F, Varaldo R, Chiusolo P, Sora F, Sica S, Laurenti L, Metafuni E. Second haploidentical stem cell transplantation for primary graft failure. Bone Marrow Transplantation. 2020 Dec 16:1-6.
14. Moreland L, Bate G, Kirkpatrick P. Abatacept. Nature Reviews Drug Discovery. 2006;5(3):185-6.
15. Zhu Z, Fan L, Wang Q. Simultaneous blockade of costimulatory signals CD28-CD80 and CD40-CD154 combined with monoclonal antibody against CD25 induced a stable chimerism and tolerance without graft-versus-host disease in rat. European Surgical Research. 2011;46(3):109-17.
16. Tiwari D, Horan J, Langston A, Qayed M, Carr J, Renfroe H, et al. A first-in-disease trial of in vivo costimulation blockade for acute GvHD prevention: the addition of abatacept to standard GvHD prophylaxis controls early CD4+ T cell proliferation and is associated with low rates of severe acute GvHD. American Society of Hematology; 2012.
17. Koura DT, Horan JT, Langston AA, Qayed M, Mehta A, Khoury HJ, et al. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. Biology of Blood and Marrow Transplantation. 2013;19(11):1638-49.
18. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biology of Blood and Marrow Transplantation. 2015;21(3):389-401. e1.
19. Przepiorka D, Weisdorf D, Martin P, Klingemann H, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone marrow transplantation. 1995;15(6):825-8.
20. Raiola AM, Dominietto A, di Grazia C, Lamparelli T, Gualandi F, Ibatici A, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biology of Blood and Marrow Transplantation. 2014;20(10):1573-9.
21. Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M, et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biology of Blood and Marrow Transplantation. 2014;20(6):890-5.
22. Solomon SR, Solh M, Morris LE, Holland HK, Bashey A. Myeloablative conditioning with PBSC grafts for T cell-replete haploidentical donor transplantation using posttransplant cyclophosphamide. Advances in hematology. 2016;2016.
23. Sharma A, Rastogi N, Chatterjee G, Kapoor R, Nivargi S, Yadav SP. Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide for Pediatric Acute Leukemia is Safe and Effective. Journal of pediatric hematology/oncology. 2020.
24. Pérez‐Martínez A, Ferreras C, Pascual A, Gonzalez‐Vicent M, Alonso L, Badell I, et al. Haploidentical transplantation in high‐risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH). American journal of hematology. 2020;95(1):28-37.
25. Katsanis E, Sapp LN, Reid SC, Reddivalla N, Stea B. T-Cell replete myeloablative haploidentical bone marrow transplantation is an effective option for pediatric and young adult patients with high-risk hematologic malignancies. Frontiers in Pediatrics. 2020;8.
26. Jaiswal SR, Chakrabarti A, Chatterjee S, Ray K, Chakrabarti S. Haploidentical transplantation in children with unmanipulated peripheral blood stem cell graft: The need to look beyond post‐transplantation cyclophosphamide in younger children. Pediatric transplantation. 2016;20(5):675-82.
27. Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, et al. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. Journal of Clinical Oncology. 2021:JCO. 20.01086.
28. Ngwube A, Shah N, Godder K, Jacobsohn D, Hulbert ML, Shenoy S. Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease. Blood Advances. 2020;4(16):3894-9.
29. Khandelwal P, Yeh RF, Yu L, Lane A, Dandoy CE, El-Bietar J, et al. Graft Versus Host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft Versus Host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta Thalassemia Major with Busulfan, Fludarabine, and Thiotepa. Transplantation. 2020.
30. Jaiswal SR, Bhakuni P, Zaman S, Bansal S, Bharadwaj P, Bhargava S, et al. T cell costimulation blockade promotes transplantation tolerance in combination with sirolimus and post-transplantation cyclophosphamide for haploidentical transplantation in children with severe aplastic anemia. Transplant immunology. 2017;43:54-9.
31. Chaudhury S, Laskowski J, Rangarajan HG, Abraham A, Haight AE, Guilcher GM, et al. Abatacept for GVHD prophylaxis after hematopoietic stem cell transplantation (HCT) for pediatric sickle cell disease (SCD): a sickle transplant alliance for research (STAR) trial. Biology of Blood and Marrow Transplantation. 2018;24(3):S91.
32. Chen Y, Fukuda T, Thakar MS, Kornblit BT, Storer BE, Santos EB, et al. Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex–haplo-identical non-myeloablative hematopoietic cell transplantation. Cytotherapy. 2011;13(10):1269-80.
33. Kean L, Hamby K, Koehn B, Lee E, Coley S, Stempora L, et al. NK cells mediate costimulation blockade‐resistant rejection of allogeneic stem cells during nonmyeloablative transplantation. American journal of transplantation. 2006;6(2):292-304.
34. Peng Y, Luo G, Zhou J, Wang X, Hu J, Cui Y, et al. CD86 is an activation receptor for NK cell cytotoxicity against tumor cells. PLoS One. 2013;8(12):e83913.
35. Jaiswal SR, Bhakuni P, Joy A, Kaushal S, Chakrabarti A, Chakrabarti S. CTLA4Ig primed donor lymphocyte infusion: a novel approach to immunotherapy after haploidentical transplantation for advanced leukemia. Biology of Blood and Marrow Transplantation. 2019;25(4):673-82.
36. McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner GL, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125(19):3024-31.
37. Khandelwal P, Chaturvedi V, Owsley E, Lane A, Heyenbruch D, Lutzko CM, et al. CD38(bright)CD8(+) T Cells Associated with the Development of Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking Cells. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020;26(1):1-6.
38. Grogan BM, Tabellini L, Storer B, Bumgarner TE, Astigarraga CC, Flowers ME, et al. Activation and expansion of CD8+ T effector cells in patients with chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation. 2011;17(8):1121-32.
39. Comoli P, Locatelli F, Moretta A, Montagna D, Calcaterra V, Cometa A, et al. Human alloantigen-specific anergic cells induced by a combination of CTLA4-Ig and CsA maintain anti-leukemia and anti-viral cytotoxic responses. Bone marrow transplantation. 2001;27(12):1263-73.